Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2017-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to determine relevant hemodynamic parameters for the diagnostics of pulmonary arterial hypertension (PAH) by dynamic contrast enhanced dual-energy CT (DE-CT). In this pilot study the investigators investigate patients who underwent right heart catheterisation with DE-CT to determine hemodynamic parameters and control the results by other clinical investigations. The investigators expect that using this non-invasive method, parameters relevant for the diagnosis of the patients with PAH, like pulmonary blood volume, blood flow and perfusion heterogeneity, can be determined.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography

NCT01829672

Pulmonary Arterial Hypertension

COMPLETED NA

Differential Diagnosis of Pulmonary Hypertension With Automated Image Analysis

NCT04329312

Pulmonary Hypertension

TERMINATED

The Early Recognition of Pulmonary Arterial Hypertension

NCT00609349

Pulmonary Arterial Hypertension

COMPLETED NA

Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension

NCT02789449

Hypertension Pulmonary

COMPLETED

Angiogenic Imaging in Pulmonary Arterial Hypertension

NCT03166306

Pulmonary Arterial Hypertension Exercise Associated Pulmonary Arterial Hypertension

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pulmonary arterial hypertension (PAH) is a rare, life-threatening disease. It is characterized by the elevation of pulmonary arterial pressure and pulmonary vascular resistance. A remodeling of small pulmonary vessels characterized by the proliferation of the adventitia, the hypertrophy of the media and fibrosis of the intima can be observed on the microscopic level.

Non-invasive techniques for hemodynamic assessment and identification of early pulmonary vascular remodeling and pulmonary hypertension have a marked practical advantage as compared to invasive right heart catheterization, however, their accuracy and reliability is not well established.

In the present study the investigators examine patients who underwent right heart catheterization and are scheduled for a thorax CT with an additional dynamic contrast-enhanced DE-CT protocol and derive established parameters for the diagnosis of PAH as well as novel parameters from the CT scans. These are compared to results from the right-heart catheterization and other investigations routinely carried out on these patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Arterial Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

pulmonary vascular disease

Dual-energy computed tomography investigation

Group Type OTHER

Dual-energy computed tomography investigation

Intervention Type RADIATION

1x 20ml Ultravist (370mg J/ml)3-5ml/s,

1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dual-energy computed tomography investigation

1x 20ml Ultravist (370mg J/ml)3-5ml/s,

1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with right heart catheterization data

Exclusion Criteria

* patients with decreased renal function
* patients who received CT in the previous six months
* intolerance of contrast material
* other standard CT contraindications

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No